Ameritas Investment Company’s TG Therapeutics TGTX Stock Holding History

Ameritas Investment Company’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-100	Closed	–	–	1712
2018 Q4	$0	Buy	+100	New	+$497	﹤0.01%	1572

Other funds holding TGTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ameritas Investment Company's TGTX Position: Q1 2019 in Review

Ameritas Investment Company sold out of TG Therapeutics (TGTX) in Q1 2019, closing a stake of 100 shares.

Ameritas Investment Company first reported a position in TGTX in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 113 funds tracked by Wall St. Rank hold TGTX as of Q1 2019.

Ameritas Investment Company reported no remaining TG Therapeutics position as of Q1 2019 after selling out during the quarter.
Ameritas Investment Company sold 100 TG Therapeutics shares in Q1 2019.
Ameritas Investment Company first reported a position in TG Therapeutics in Q4 2018 and held it in 1 quarter.
Ameritas Investment Company's TG Therapeutics position peaked at $0 in Q4 2018.
113 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2019.

Based on Ameritas Investment Company's 13F filing for Q1 2019, filed 16 May 2019.